To BRCA or Not to PALB (Correspondence/Original research paper)

JCO - Letter

 To the Editor:
 Published online before print June 29, 2015

Kaufman et al¹ report interesting data from a nonrandomized phase II multicenter study of an oral poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, monotherapy in a spectrum of germline BRCA1 and BRCA 2 (BRCA 1/2) –mutated cancers (ovarian, breast, pancreatic, and prostate cancer). This article by Kaufman et al adds to the growing body of evidence of the potential for PARP inhibitor inclusion in the therapeutic management of patients with BRCA 1/2 mutations.^2–5....

 

REFERENCES

1. 1.↵
   1. Kaufman B,
   2. Shapira-Frommer R,
   3. Schmutzler RK,
   4. et al.

   (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250.
   Published online before print November 3, 2014, doi: 10.1200/JCO.2014.56.2728 JCO January 20, 2015 vol. 33 no. 3 244-250

   Abstract/FREE Full Text